Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Depreciation

Similar metrics at other companies

LHBiopharma Laboratory Services — Depreciation

$28.6M0.0%

TMOLaboratory Products and Biopharma Services — Depreciation of property, plant and equipment

$186M+8.1%

PTCTLife Science — Depreciation

$3.81M+10.1%

DHRBiotechnology — Depreciation

$40M+17.6%

PFEBiopharma — D&A

$348M+5.1%

BAXPharmaceuticals — Depreciation

$16M0.0%

Questions, answered.

What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation?

Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — depreciation of $119K in Q1 2026.

How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation changed year-over-year?

Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation decreased by 76.8% year-over-year, from $513K to $119K.

What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation?

Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation has grown at a -36.3% compound annual growth rate (CAGR), from $3.84M to $991K.

What does development and licensing of biopharmaceutical assets — depreciation mean?

This metric tracks the periodic allocation of the cost of tangible property and equipment used within the biopharmaceutical development and licensing segment. It accounts for the wear and tear or obsolescence of physical assets required to support operations. While generally a minor expense for this segment, it provides insight into the capital intensity of the business.